Allogene Therapeutics, Inc. (ALLO) Stock Score, Valuation & Financial Research

Allogene Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ALLO

Allogene Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.60. These figures are a research snapshot, not a buy or sell recommendation.

What Allogene Therapeutics, Inc. does

Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Allogene Therapeutics is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on funding research and development to advance a pipeline of allogeneic CAR T cell product candidates, with the goal of eventually commercializing these therapies for cancer and autoimmune diseases.

Products and services

  • The company develops allogeneic CAR T cell product candidates, including cema-cel and ALLO-316, which are engineered from healthy donor T cells for off-the-shelf use in patients.

Customer types

Clinical trial patients.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Cellectis S.A. — The company maintains a license agreement to utilize Cellectis's TALEN-based gene-editing technology for the development of its allogeneic CAR T cell product candidates. Source
  • Servier — The company holds an exclusive license agreement with Servier to commercialize certain CAR T products directed at specific targets. Source

Competitors and product-market comparisons

  • Autologous CAR T therapy developers — Companies developing autologous CAR T cell therapies, which require patient-specific cell collection and processing. Source

Business strengths to evaluate

  • Proprietary allogeneic CAR T platform technology Source

Business risks and research considerations

  • Dependence on third-party intellectual property and potential litigation (e.g., Factor Litigation) Source
  • Clinical trial failure and regulatory approval uncertainty Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ALLO financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.60
Market capitalization:
552.25M (currency not supplied)
Revenue:
USD 4.64M
Net income:
USD -165.49M
Free cash flow:
USD -149.63M
Cash:
USD 38.63M
Total debt:
USD 70.35M
EPS:
USD -0.67

What stands out

  • Free cash flow is USD -149.63M, negative for the stored period.
  • The balance sheet shows USD 38.63M of cash versus USD 70.35M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -3224.8% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -3566.7% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Debt exceeds cash by USD 31.73M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ALLO

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ALLO fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does ALLO's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for ALLO to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of ALLO's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ALLO

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.